Distribution of patients for each CHADS₂ and CHA₂DS₂-VASc score.

<p>(A) Patients without oral anticoagulant (OAC). (B) Patients with OAC. SD: standard deviation.</p

Cumulative events and incidence of events during follow-up in patients without OAC at baseline (N = 1,541).

<p>OAC: oral anticoagulant, SE: systemic embolism.</p><p>Cumulative events and incidence of events during follow-up in patients without OAC at baseline (N = 1,541).</p

Predictors for the incidence of death/stroke/SE in patients without OAC; Univariate and multivariate analysis.

<p>SE: systemic embolism, HR: hazard ratio, CI: confidence interval, BMI: body mass index, TIA: transient ischemic attack, COPD: chronic obstructive pulmonary disease.</p><p>Predictors for the incidence of death/stroke/SE in patients without OAC; Univariate and multivariate analysis.</p

Comparison of baseline characteristics and co-morbidities between patients with and without OAC at baseline.

<p>Categorial data are presented as number (%). Continuous data are presented as mean ± standard deviation. OAC: oral anticoagulants, BMI: body mass index, SE: systemic embolism, TIA: transient ischemic attack, COPD: chronic obstructive pulmonary disease.</p><p>Comparison of baseline characteristics and co-morbidities between patients with and without OAC at baseline.</p

Baseline characteristics, medications, angiographic and procedural characteristics during the index hospitalization in the propensity score-matched cohort.

(DOCX)</p

Kaplan-Meier event curves for clinical outcomes in patients with two-vessel or three-vessel disease including proximal LAD.

(TIF)</p

List of clinical research coordinators.

(DOCX)</p

Baseline characteristics and medications during the index hospitalization: PCI group versus CABG group.

Baseline characteristics and medications during the index hospitalization: PCI group versus CABG group.</p

Clinical outcomes: PCI group versus CABG group in patients with two-vessel disease who underwent multi-vessel revascularization including LAD.

(DOCX)</p

Kaplan-Meier event curves for clinical outcomes in patients with two-vessel disease including LAD.

(TIF)</p